Item 2.02 Results of Operations and Financial Condition.
On March 6, 2023, Day One Biopharmaceuticals, Inc. issued a press release
announcing its financial results for the quarter and year ended December 31,
2022. A copy of the press release is attached as Exhibit 99.1 to this report.
Item 7.01 Regulation FD Disclosure.
On March 6, 2023, Day One Biopharmaceuticals, Inc. updated its corporate
presentation. A copy of the updated presentation is attached as Exhibit 99.2 to
The information in this Current Report on Form 8-K, including Exhibit 99.1 and
Exhibit 99.2 to this report, shall not be deemed to be “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section or Sections 11
and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).
The information contained in this Current Report on Form 8-K and in the
accompanying Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by
reference into any other filing under the Exchange Act or under the Securities
Act, except as shall be expressly set forth by specific reference in such
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Exhibit Description Number 99.1 Press release issued by Day One Biopharmaceuticals, Inc. regarding its financial results for the quarter and year ended December 31, 2022, dated March 6, 2023. 99.2 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source Glimpses